Evidence map›Paper›PMID 21860421›Full record

ArticleOncogene2012

Oncogenic activation of FOXR1 by 11q23 intrachromosomal deletion-fusions in neuroblastoma.

E E Santo, M E Ebus, J Koster, J H Schulte, A Lakeman, P van Sluis, J Vermeulen, D Gisselsson, I Øra, S Lindner and 7 more

Abstract read
PubMed Publisher
In one paragraph

Article in Oncogene, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.

0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed
2.8field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

36 citing papers in PubMed, 68 citations in OpenAlex.

  1. Article
  2. Review
  3. Aggressive Malignant Ossifying Fibromyxoid Tumor With a RareInternational journal of surgical pathology · 2025
    Review
  4. Article
  5. Article
  6. Article
  7. FOXR2 Stabilizes MYCN Protein and Identifies Non-Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2021
    Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. The Dominant Role of Forkhead Box Proteins in Cancer.International journal of molecular sciences · 2018
    Review
  17. Article
  18. PeerJ · 2018
    Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 7 institutions in 5 countries.

E E SantoDepartment of Oncogenomics, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
M E Ebus
J Koster
J H Schulte
A Lakeman
P van Sluis
J Vermeulen
D Gisselsson
I Øra
S Lindner
P G Buckley
R L Stallings
J Vandesompele
A Eggert
H N Caron
R Versteeg
J J Molenaar
Academic Medical Center · NLEssen University Hospital · DEUniversity of Amsterdam · NLGhent University Hospital · BELund University · SENational Children’s Research Centre · IERoyal College of Surgeons in Ireland · IE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Neuroblastoma tumors frequently show loss of heterozygosity of chromosome 11q with a shortest region of overlap in the 11q23 region. These deletions are thought to cause inactivation of tumor suppressor genes leading to haploinsufficiency. Alternatively, micro-deletions could lead to gene fusion products that are tumor driving. To identify such events we analyzed a series of neuroblastomas by comparative genomic hybridization and single-nucleotide polymorphism arrays and integrated these data with Affymetrix mRNA profiling data with the bioinformatic tool R2 (http://r2.amc.nl). We identified three neuroblastoma samples with small interstitial deletions at 11q23, upstream of the forkhead-box R1 transcription factor (FOXR1). Genes at the proximal side of the deletion were fused to FOXR1, resulting in fusion transcripts of MLL-FOXR1 and PAFAH1B2-FOXR1. FOXR1 expression has only been detected in early embryogenesis. Affymetrix microarray analysis showed high FOXR1 mRNA expression exclusively in the neuroblastomas with micro-deletions and rare cases of other tumor types, including osteosarcoma cell line HOS. RNAi silencing of FOXR1 strongly inhibited proliferation of HOS cells and triggered apoptosis. Expression profiling of these cells and reporter assays suggested that FOXR1 is a negative regulator of fork-head box factor-mediated transcription. The neural crest stem cell line JoMa1 proliferates in culture conditional to activity of a MYC-ER transgene. Over-expression of the wild-type FOXR1 could functionally replace MYC and drive proliferation of JoMa1. We conclude that FOXR1 is recurrently activated in neuroblastoma by intrachromosomal deletion/fusion events, resulting in overexpression of fusion transcripts. Forkhead-box transcription factors have not been previously implicated in neuroblastoma pathogenesis. Furthermore, this is the first identification of intrachromosomal fusion genes in neuroblastoma.

Indexed as

Chromosomes, Human, Pair 11Recombination, GeneticAnimalsCell Line, TumorComparative Genomic HybridizationGene Expression Regulation, NeoplasticGene SilencingHaploinsufficiencyHumansLoss of HeterozygosityMiceNeuroblastomaOncogene FusionPolymorphism, Single NucleotideSequence Deletion

Identifiers

PMID21860421
OpenAlexW1999572761

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.